Skip to main content

Table 1 General distribution and outcome type of new cases of drug-resistant pulmonary tuberculosis, according to characteristics of block I, Brazil, 2013 and 2014

From: Brazilian cohort study of risk factors associated with unsuccessful outcomes of drug resistant tuberculosis

  Total (980 cases) Success treatment Lost to follow-up Failure Death
  N % N % N % N % N %
Block I           
Sex           
Male 652 66.5 412 63.2 120 18.4 46 7.1 74 11.3
Female 328 33.5 209 63.7 43 13.1 30 9.1 46 14.0
Race/color           
White 380 38.8 255 67.1 60 15.8 32 8.4 33 8.7
Brown/Blacka 593 60.5 360 60.7 102 17.2 44 7.4 87 14.7
Asian/Indigenous 7 0.7 6 85.7 1 14.3 0 0.0 0 0.0
Age group (years)           
15–59 883 90.1 563 63.8 157 17.8 69 7.8 94 10.6
60 or over 97 9.9 58 59.8 6 6.2 7 7.2 26 26.8
Education (years)           
0 to 7 574 58.6 342 59.6 109 19.0 41 7.1 82 14.3
8 or more 318 32.4 229 72.0 36 11.3 31 9.7 22 6.9
Missing 88 9.0 50 56.8 18 20.5 4 4.5 16 18.2
HIV           
Positive 105 10.7 52 49.5 21 20.0 7 6.7 25 23.8
Negative 753 76.8 495 65.7 121 16.1 60 8.0 77 10.2
Missing 122 12.4 74 60.7 21 17.2 9 7.4 18 14.8
Alcoholism           
Yes 246 25.1 135 54.9 55 22.4 19 7.7 37 15.0
No/don't know 734 74.9 486 66.2 108 14.7 57 7.8 83 11.3
Diabetes           
Yes 144 14.7 98 68.1 14 9.7 10 6.9 22 15.3
No/don't know 836 85.3 523 62.6 149 17.8 66 7.9 98 11.7
Smoking           
Yes 241 24.6 139 57.7 47 19.5 18 7.5 37 15.4
No/don't know 739 75.4 482 65.2 116 15.7 58 7.8 83 11.2
Use of illicit drugs           
Yes 162 16.5 79 48.8 52 32.1 10 6.2 21 13.0
No/don't know 818 83.5 542 66.3 111 13.6 66 8.1 99 12.1
Other associated diseases or conditionsb           
Yes 164 16.7 97 59.1 21 12.8 14 8.5 32 19.5
No/don't know 816 83.3 524 64.2 142 17.4 62 7.6 88 10.8
Prison population           
Yes 46 4.7 30 65.2 14 30.4 1 2.2 1 2.2
No 934 95.3 591 63.3 149 16.0 75 8.0 119 12.7
Total 980 100.0 621 63.4 163 16.6 76 7.8 120 12.2
  1. aBrown/Black = combines black and brown
  2. bSilicosis, neoplasms, transplant, user of TNF–alpha inhibitors and corticosteroids, seizure, viral hepatitis, renal failure/hemodialysis, and mental disorder